Search Results - Martin Eduardo Richardet

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial

    696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial by Toni K. Choueiri, Thomas Powles, Mauricio Burotto, María T. Bourlon, Bogdan Żurawski, Víctor Manuel Oyervides-Juárez, James J. Hsieh, Umberto Basso, Amishi Y. Shah, Cristina Suárez, A. Hamzaj, Carlos H. Barrios, Martin Eduardo Richardet, David Pook, Yoshihiko Tomita, Bernard Escudier, J. Zhang, Burçin Şimşek, Andrea B. Apolo, Robert J. Motzer

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

    Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial by Thomas Powles, Mauricio Burotto, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Camillo Porta, Carlos H. Barrios, Martin Eduardo Richardet, Howard Gurney, Elizabeth R. Kessler, Yoshihiko Tomita, Jens Bedke, Saby George, Christian Scheffold, P. Wang, В. Э. Федоров, Robert J. Motzer, Toni K. Choueiri

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Subcutaneous versus intravenous nivolumab for renal cell carcinoma

    Subcutaneous versus intravenous nivolumab for renal cell carcinoma by Laurence Albigès, María T. Bourlon, Matías Chacón, Hernán Cutuli, Yamil Alonso Lopez Chuken, Bogdan Żurawski, José Maurício Mota, Ignacio Magrí, Mauricio Burotto, Murilo Luz, Juliana De Menezes, Eduardo Patricio Yanez Ruiz, Simon Fu, Martin Eduardo Richardet, Begoña P. Valderrama, Marco Maruzzo, Sergio Bracarda, Mary Alice B. Breckenridge, Heather Vezina, Darshana Rathod, Zhuoxin Yu, Yingchao Zhao, Matthew Dixon, Deepak Perumal, Shaji George

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS

    Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS by Neal D. Shore, Christian Gratzke, Susan Feyerabend, Patrick Werbrouck, Joan Carles, Egils Vjaters, Teuvo L.J. Tammela, David Morris, Jeanny B. Aragon‐Ching, Raoul S. Concepcion, Urban Emmenegger, Neil Fleshner, Markus Grabbert, V. Lietuvietis, Hakim Mahammedi, Francisco Cruz, Adriano Augusto Peclat de Paula, Christopher Pieczonka, Antti Rannikko, Martin Eduardo Richardet, Glauco Costa Silveira, Iris Kuss, Marie‐Aude Le Berre, Frank Verholen, Toni Sarapohja, Matthew Ryan Smith, Karim Fizazi

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

    Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden by Michael Schenker, Mauricio Burotto, Martin Eduardo Richardet, Tudor‐Eliade Ciuleanu, Anthony Gonçalves, Neeltje Steeghs, Patrick Schöffski, Paolo A. Ascierto, Michele Maio, Iwona Ługowska, Lorena Lupinacci, Alexandra Léary, Jean‐Pierre Delord, Julieta Grasselli, David S.P. Tan, Jennifer Friedmann, Jacqueline Vuky, Marina Tschaika, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Georgia Kollia, Misena Pacius, Quyen Duong, Ning Huang, Parul Doshi, Jonathan Baden, Massimo Di Nicola

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma by Toni K. Choueiri, Thomas Powles, Mauricio Burotto, Bernard Escudier, María T. Bourlon, Bogdan Żurawski, Víctor Manuel Oyervides-Juárez, James J. Hsieh, Umberto Basso, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Jeffrey C. Goh, Carlos H. Barrios, Martin Eduardo Richardet, Camillo Porta, Rubén Dario Kowalyszyn, Juan P. Feregrino, Jakub Żołnierek, David Pook, Elizabeth R. Kessler, Yoshihiko Tomita, Ryuichi Mizuno, Jens Bedke, Joshua Zhang, Matthew Maurer, Burçin Şimşek, Flavia Ejzykowicz, Gisela Schwab, Andrea B. Apolo, Robert J. Motzer

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

    Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial... by Robert J. Motzer, Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Elizabeth R. Plimack, Giuseppe Procopio, David F. McDermott, Daniel Castellano, Toni K. Choueiri, Frede Donskov, Howard Gurney, Stéphane Oudard, Martin Eduardo Richardet, Katriina Peltola, Ajjai Alva, Michael A. Carducci, John Wagstaff, Christine Chevreau, Satoshi Fukasawa, Yoshihiko Tomita, Thomas Gauler, Christian Kollmannsberger, Fabio A.B. Schutz, James Larkin, David Cella, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

    Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial by Martin Schüler, James Chih‐Hsin Yang, K. Park, Jie‐Hyun Kim, Jaafar Bennouna, Y.-M. Chen, C. Chouaïd, Filippo de Marinis, Jinlun Feng, Francesco Grossi, D.-W. Kim, X. Liu, Shun Lü, János Strausz, Yuriy Vinnyk, Rainer Wiewrodt, Caicun Zhou, B. Wang, Vikram K. Chand, David Planchard, Sai‐Hong Ignatius Ou, David Planchard, Keunchil Park, Martin Schüler, James Chih‐Hsin Yang, Vikram K. Chand, Klaus Röhr, Claudia Bagnes, Claudio Martín, Gonzálo Recondo, Juan José Zarbá, C. Blajman, Martin Eduardo Richardet, Sue‐Anne McLachlan, Phillip Parente, Craig Underhill, Catherine Crombie, Paul N. Mainwaring, Richard Greil, Yves Humblet, F. Bustin, L Carestia, Danny Galdermans, Marc Lambrechts, Laetitia Delval, Piet Vercauter, Caicun Zhou, Jin Wang, Cheng Huang, Xiaoyan Lin, Yi‐Long Wu, Xiaoqing Liu, Ying Cheng, Shukui Qin, Jifeng Feng, Jianjin Huang, Yiping Zhang, Shun Lü, Manuela Zereu, Bernardo Garicochea, Cyntia Albuquerque Zadra, Henrik Riska, Tuomo Alanko, Jacques Cadranel, C. Chouaïd, Gérard Zalcman, Denis Moro‐Sibilot, M. Pérol, David Planchard, Jaafar Bennouna, P. Fournel, Radj Gervais, M. Rotarski, Bruno Coudert, Martin Schüler, Michael Thomas, Thomas Wehler, Martin Faehling, Ulrich Keilholz, Eckart Laack, Joachim von Pawel, Rudolf M. Huber, N Dickgreber, Rainer Wiewrodt, Z. Mark, S. Tehenes, János Strausz, Veronika Sárosi, Kumar Prabhash, Minish Jain, Venkatesan Srinivasan, Lalit Mohan Sharma, H. Dadhich, Rajnish Nagarkar, Amir Onn, Maya Gottfried, Salomon M. Stemmer, Maria Rita Migliorino, Francesco Grossi, Paolo Bidoli

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: